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Abstract
Background: Vasohibin 2 (VASH2) has previously been identified as an agiogenenic factor and a cancer related
protein. Here we investigated the association of VASH2 expression and chemoresistance in pancreatic cancer.
Methods: Immunohistochemical staining for VASH2 was performed on 102 human pancreatic cancer samples.
Pancreatic cancer cell line models exhibiting overexpression or knockdown of VASH2 were generated. Gene
expression analyses were carried out to determine genes differentially regulated by VASH2. Putative transcription
factors that are downstream mediators of gene expression regulated by VASH2 were queried bioinformatically.
Dual-luciferase reporter assays and ChIP assays were performed to confirm transactivation of target genes following
VASH2 overexpression or knockdown.
Results: VASH2 protein expression was higher in human pancreatic cancer than in paired adjacent tissues and
elevated VASH2 levels were associated with gemcitabine chemoresistance. In cell line models of pancreatic cancer,
VASH2 expression induced gemcitabine chemoresistance in vitro and in vivo. It was discovered that expression
of ribonucleotide reductase regulatory subunit M2 (RRM2) is regulated by VASH2; immunohistochemical analysis
demonstrated a positive association of VASH2 expression and RRM2 expression in human pancreatic cancer tissues.
Bioinformatics analyses revealed that induction of the Jun proto-oncogene (JUN) by VASH2 is responsible for
upregulation of RRM2 expression; this JUN-dependent regulation of RRM2 by VASH2 was confirmed by chromatin
immunoprecipitation and dual luciferase reporter assays, which demonstrated that JUN directly binds with the
RRM2 promoter to activate transcription.
Conclusions: These data suggest that VASH2 reduces the chemosensitivity to gemcitabine in pancreatic cancer
cells via JUN-dependent transactivation of RRM2.
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Background
Pancreatic cancer carries a uniformly poor prognosis
with low surgical resection rate and short survival time,
and improvement in prognosis, even for resectable cases,
is a persistent clinical challenge. Gemcitabine is the first-
line chemotherapy drug for adjuvant treatment of
pancreatic cancer, but has demonstrated limited ability
to improve the prognosis of patients with pancreatic
cancer. The poor efficacy of gemcitabine in pancreatic
cancer is due to chemoresistance of the cancer cells. The
mechanism of chemoresistance to gemcitabine is elusive,
and it is necessary to define gemcitabine-resistance
mechanisms in pancreatic cancer to identify novel
targets and develop means to overcome chemoresistance
to gemcitabine.
The Vasohibin family contains two members: Vasohibin
1 (VASH1) and Vasohibin 2 (VASH2) [1]. VASH1 is
located in the cytoplasm of endothelial cells and was first
identified as a negative regulator of angiogenesis [2, 3].
VASH2 is a homolog of VASH1, and was shown to stimu-
late angiogenesis in a mouse model of hypoxia-induced
subcutaneous angiogenesis [3]. We have demonstrated
that VASH2 protein expression can be detected in both
the nuclear and cytoplasmic compartments [4]. Recently,
VASH2 has been demonstrated to be involved in the
malignant behavior of a number of malignancies, includ-
ing hepatic cancer [5, 6], ovarian cancer [7, 8], endometrial
cancer [9], gastrointestinal cancers [10], breast cancer
[11], and pancreatic cancer [12]. Kim JC et al. have
reported that VASH2 promotes tumor progression and is
associated with a poor clinical outcome in pancreatic
ductal adenocarcinoma [12]. However, the relation
between VASH2 expression and efficacy of chemotherapy
remains to be elucidated.
We previously produced rabbit polyclonal anti-human
VASH2 antibodies which were successfully applied in
immunoblotting and immunohistochemical analyses of
human liver cancer and adjacent normal tissues [4, 13],
breast cancer [11], and multiple other human cancer
and normal tissues [14]. Here, we investigated the ex-
pression of VASH2 in human pancreatic cancer and ana-
lyzed the relationship between VASH2 expression and
clinical features. We also investigated the function and
mechanism of VASH2 in human pancreatic cancer using
in vitro and in vivo models. We demonstrate that
VASH2 is overexpressed in human pancreatic cancer
and functions as a gemcitabine-resistance factor by Jun
proto-oncogene (JUN) dependent transactivation of ri-
bonucleotide reductase regulatory subunit M2 (RRM2).
Methods
Clinical samples
Human pancreatic cancer tissue (pancreatic ductal
adenocarcinoma) and paired adjacent normal pancreas
tissue were obtained from 102 patients who underwent
surgical resection at Jiangsu Province Hospital during
January 2012 to December 2013. All patients were
treatment-naive to chemotherapy and radiotherapy prior
to surgery. This study was approved by the Ethics
Committee of the First Affiliated Hospital with Nanjing
Medical University. All surgical specimens were obtained
after explanation to the patient and after his/her written
and signed informed consent. A portion of the pancre-
atic cancer patients (30/102) received adjuvant chemo-
therapy: gemcitabine was administered on days 1, 8, and
15 for four to six cycles (four weeks per cycle) post-
operation. The remaining portion of pancreatic cancer
patients (72/102) received no adjuvant chemotherapy or
radiotherapy. Patients who were alive at last follow-up
were censored for survival analysis.
Animals
Five-week-old male nude mice (BALB/cA-nu [nu/nu])
were obtained from Vital River Laboratories (Beijing,
China). All experimental procedures were approved by
the Animal Care and Use Subcommittee of Nanjing
Medical University.
Cell culture
SW1990 and PANC-1 human pancreatic cancer cells
were obtained from the Shanghai Cell Bank (Type
Culture Collection Committee, Chinese Academy of
Sciences). Cells were maintained in DMEM (Gibco,
Thermo Fisher Scientific, USA) containing 10% FBS
(Gibco). All cells were cultures in a humidified incubator
at 37°C and 5% CO2.
Establishment of stable cell lines using plasmid and
lentivirus
Lentiviral constructs were designed for the overexpres-
sion or knockdown VASH2, as previously described [5].
PANC-1 cells were stably transfected with Lv-CMV-
VASH2 to overexpress VASH2 (PANC-1-VASH2);
PANC-1 cells were stably transfected with the control
plasmid Lv-CMV-EGFP (PANC-1-EGFP); SW1990 cells
were stably transfected with VASH2-targeting lentiviral
shRNA for stable knockdown of VASH2 (SW1990-
shVASH2); SW1990 cells were stably transfected with
scrambled lentiviral shRNA (SW1990-scramble). JUN
expressing plasmid was obtained from GeneCopoeia
(EX-B0091, Guangzhou, China).
Quantitative RT–PCR
Total RNA was extracted using RNAiso plus reagent and
cDNA was prepared using the Primescript RT Reagent
(TAKARA, Dalian, China). Quantitative RT–PCR was
performed using the ABI Step One Plus Real-Time-PCR
System (Applied Biosystems, USA) with SYBR Green
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Master Mix (Applied Biosystems). RT-PCR was performed
for RRM2, JUN, and GAPDH. GAPDH expression was
used as a reference to determine fold changes for the
target genes using the comparative Ct method [5]. The
sequences for primers against RRM2, JUN, and GAPDH
are provided in Additional file 1.
Immunoblotting
Whole cell lysates were prepared in radioimmunopreci-
pitation assay buffer (Beyotime, Nantong, China) and
blotted using the following primary antibodies: rabbit
polyclonal anti-VASH2 (prepared as described in [4]);
rabbit polyclonal anti-RRM2 (cat. no. ab57653, Abcam,
USA); rabbit polyclonal anti-JUN (cat. no. sc-1694, Santa
Cruz, USA). The secondary antibodies used for detection
were horseradish peroxidase-conjugated goat anti-mouse
IgG and horseradish peroxidase-conjugated donkey anti-
rabbit IgG (both CWBIO, Beijing, China).
Immunohistochemistry
Immunohistochemical staining of the clinical samples
was performed as previously described [4]. Primary anti-
bodies: rabbit polyclonal anti-VASH2 [4]; rabbit poly-
clonal anti-RRM2 (cat. no. ab57653, Abcam). VASH2
and RRM2 staining intensity were semi-quantitatively
scored by two pathologists as follows: negative: 0; weak
staining: 1; moderate staining: 2; and strong staining: 3.
Unless otherwise specified (as in the cancer vs. adjacent
normal tissue analysis), degree of VASH2 staining refers
to staining within pancreatic cancer cells.
Analysis of cellular apoptosis
Using Annexin V-PE/7-AAD Apoptosis Detection Kit
(Becton Dickinson, San Jose, CA, USA), cellular apop-
tosis was assessed by flow cytometry (Becton Dickinson).
Cells were cultured with gemcitabine (25nM or 50nM)
for 48 h [15]. Cells were collected, washed with PBS,
and suspended in 100 μL binding buffer, stained with
5μL of Phycoerythrin (PE)–Annexin-V and 5 μL of 7-
AAD for 15 min in the dark. The stained cells were ana-
lyzed immediately.
In vivo tumorigenesis
5 × 106 of PANC-1-EGFP or PANC-1-VASH2 were bilat-
erally subcutaneously injected into the flanks of nude
mice; as control, 1 × 106 SW1990-scramble or SW1990-
shVASH2 cells were bilaterally subcutaneously injected
into the flanks of mice. Once tumor size reached 0.5-
1.0cm, mice were euthanized and the xenograft tumors
were harvested, cut into small pieces (1mm3), and then
subcutaneously re-implanted into nude mice. This
process was performed twice. Finally, PANC-1-EGFP/
PANC-1-VASH2 (n = 12) or SW1990-scramble/SW1990-
shVASH2 (n = 14) xenograft tumor pieces were
subcutaneously implanted in the back of the same mice in
symmetrical positions on both sides. Mice were divided
into four groups: PANC-1 group (n = 6): mice implanted
with PANC-1-EGFP/PANC-1-VASH2 tumor pieces with-
out gemcitabine chemotherapy; PANC-1-GZ group (n = 6):
mice implanted with PANC-1-EGFP/PANC-1-VASH2
tumor pieces with gemcitabine chemotherapy; SW1990
group (n = 7): mice implanted with SW1990-scramble/
SW1990-shVASH2 tumor pieces without gemcitabine
chemotherapy; SW1990-GZ group (n = 7): mice implanted
with SW1990-scramble/SW1990-shVASH2 tumor pieces
with gemcitabine chemotherapy. Administration of chemo-
therapy began when the tumor diameter reached 3-5mm:
every Tuesday and Saturday gemcitabine was injected
intraperitoneally at 100mg/kg; the SW1990-GZ group was
treated for 3 weeks; the PANC-1-GZ group was treated for
four consecutive weeks. Tumors were weighed by
electronic scales. Tumor control rate was calculated as the
following formula:
Tumor control rate ¼ ðcontrol group tumor weight
– VASH2 overexpressing=knockdown
group tumor weightÞ
 100=control group tumor weight:
A higher tumor control rate indicates that the tumor
size is smaller in experimental compared to control
group, and a lower tumor control rate indicates that
tumor size is greater in experimental group compared to
control.
TdT-Mediated dUTP-Biotin Nick End-Labeling (TUNEL)
Xenograft tumor tissues were embedded in paraffin and
sectioned for the TUNEL assay. TUNEL staining was
performed by Biohelper Nanjing company (Biohelper,
Nanjing, China) using an in situ cell death detection kit
(Roche, Switzerland) according to the manufacturer's in-
structions. TUNEL assay results were determined by
counting 1,000 cells in six randomly selected fields per
sample.
Gene expression array
Samples of PANC-1-EGFP or PANC-1-VASH2 cells
were prepared for gene expression analysis using
NimbleGen 12x135K microarrays (Roche Applied Sci-
ence, Switzerland). Arrays were scanned using an Axon
GenePix 4000B microarray scanner (Molecular Devices,
CA, USA). Scanned images were imported into Nimble-
Scan software (version 2.6, Roche Applied Science,
Switzerland) for gene expression data analysis. Differen-
tially expressed genes were identified through Fold
Change filtering. Genes with fold changes ≥ 3 or ≤ 0.33
were selected for further analysis.
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siRNA
Three small interfering RNAs (GenePharma, Shanghai,
China) were used for JUN knockdown; siRNA sequence
information is provided in Additional file 1. Lipofecta-
mine RNAiMAX transfection reagent (Invitrogen,
Thermo Fisher Scientific, USA) was used for siRNA
transfection.
Chromatin immunoprecipitation (ChIP)
ChIP was performed using the Magna ChIP Chromatin
Immuno Precipitation kit (Millipore, Billerica, MA,
USA). Immunoprecipitations were carried out with anti-
c-Jun (H79) (cat. no. sc1694, Santa Cruz) antibody.
Precipitated DNA was purified and used as a template
for PCR reactions. Primers used for PCR in chroma-
tin immunoprecipitation experiments are described in
Additional file 1.
Dual luciferase reporter assay
The RRM2 promoter (-2147/+1 relative to the transcrip-
tion start site) [16] containing a JUN binding site (-643/-
630 relative to the transcription start site) was synthesized
(GenScript, Nanjing, China) and ligated into pGL3 basic
reporter vector (Promega, Madison, WI, USA) to create
PGL3-WT. A reporter vector containing a mutated JUN
binding site in the RRM2 promoter was constructed
(PGL3-MUT; TTTACATGAGTCAT→GCGCAGGACA
CAGC). Reporter plasmids were co-transfected with a
Renilla luciferase expression plasmid (pRL-TK; Promega)
as transfection control. Cells were cultured for 24 h fol-
lowing transfection, and luciferase activity was measured
using the Dual Luciferase Reporter Assay System (Pro-
mega). The relative promoter activity was calculated as
firefly luminescence/Renilla luminescence.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 (SPSS,
Chicago, IL, USA) and GraphPad Prism 5.01 (GraphPad
Software Inc., San Diego, CA, USA). Data were shown
as mean ± S.E.M. The experimental and control groups
were compared using the Student’s t-test. The Pearson’s
Chi-square test was used to compare differences in pro-
portions of VASH2 staining intensity. Kaplan-Maier sur-
vival analysis was used to compare survival times.
Spearman correlation coefficients were calculated to
compare the expression of VASH2 and RRM2. Signifi-
cant differences are indicated with * (P < 0.05).
Results
Correlation between VASH2 expression and
histopathologic features of pancreatic cancer
We investigated the levels of VASH2 expressed in 102
human pancreatic cancer tissue samples and paired adja-
cent tissues by immunohistochemical analysis. General
clinical information of the patients is shown in Table 1.
Correlations between VASH2 staining intensity and
histopathologic features of the 102 pancreatic cancer
cases are shown in Table 2. Representation of immu-
nostaining pictures for weak and strong VASH2
staining in pancreatic cancer tissues were shown in
Additional file 2. The proportion of specimens exhibit-
ing middle/strong staining for VASH2 was significantly
higher in pancreatic cancer tissue samples (56.9%, 58/
102) than in adjacent normal tissue samples (24.5%,
25/102; P = 0.001). The proportion of specimens with
middle/strong staining for VASH2 expression was
generally higher in grade 3 pancreatic cancers than in
grade 1-2 pancreatic cancers (37/54 [68.5%] vs. 21/48
[43.8%], respectively; P = 0.012). The proportion of
specimens with middle/strong VASH2 staining was
significantly lower in vessel cancerous embolus nega-
tive pancreatic cancer tissues than in vessel cancerous
embolus positive pancreatic cancer tissues (47/89
[52.8%] vs. 11/13 [84.6%], respectively; P = 0.031).
Degree of VASH2 staining was not found to associate
with pathologic stage, node status, or nerve status of
pancreatic cancer samples.
VASH2 expression is associated with gemcitabine
resistance in pancreatic cancer
In cases with negative/weak VASH2 staining, patients
treated with gemcitabine chemotherapy exhibited sig-
nificantly better survival than patients not treated
with chemotherapy (20.96 ± 2.87 months vs. 12.45 ±
1.34 months, respectively; P = 0.022; Fig. 1a). In con-
trast, among cases with middle/strong VASH2 stain-
ing, there was no significant difference in survival
time between patients treated with gemcitabine
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chemotherapy and those not treated with chemother-
apy (11.99 ± 0.74 months vs. 11.26 ± 0.73 months, re-
spectively; P = 0.276; Fig. 1b). Among patients treated
with gemcitabine chemotherapy, cases with middle/
strong VASH2 staining exhibited significantly poorer
survival than cases with negative/weak VASH2 stain-
ing (Fig. 1c, P = 0.045). There was no significant dif-
ference in survival time associated with degree of
VASH2 staining in patients who were not treated
with chemotherapy (Fig. 1d, P = 0.295). These results
indicate that VASH2 expression may be associated
with gemcitabine resistance in pancreatic cancer.
VASH2 decreased the sensitivity of pancreatic cancer cells
to gemcitabine in vitro
To further assess the effect of VASH2 on the sensitivity
of pancreatic cancer cells to chemotherapy, we generated
human pancreatic cancer cells overexpressing VASH2
(PANC-1-VASH2) and in which VASH2 had been
knocked down using a small hairpin RNA (SW1990-
shVASH2). Immunoblotting confirmed that the expres-
sion of VASH2 in PANC-1-VASH2 cells exceeded that
of parental PANC-1 cells transduced to express EGFP;
SW1990-shVASH2 cells expressed lower levels of
Fig. 1 VASH2 expression is associated with gemcitabine resistance in pancreatic cancer. Kaplan-Meier survival analysis results of 102 cases of
pancreatic cancer. a survival analysis of patients with negative/weak VASH2 staining tumors treated with or without gemcitabine chemotherapy.
b survival analysis of patients with middle/strong VASH2 staining tumors treated with or without gemcitabine chemotherapy. c survival analysis
of patients treated with gemcitabine chemotherapy with negative/weak or middle/strong VASH2 staining tumors. d survival analysis of patients
who received no chemotherapy with negative/weak or middle/strong VASH2 staining tumors
Table 2 Correlation between VASH2 and histopathologic
features in 102 cases of pancreatic cancer
Category n (%) VASH2 staining (%) P value1
Negative/weak Middle/strong
Adjacent tissues 102 77(75.5) 25(24.5) 0.001
Cancer tissue 102 44(43.1) 58(56.9)
Tumor Grade
G1-G2 48 (47.1) 27(56.2) 21(43.8) 0.012
G3 54 (52.9) 17(31.5) 37(68.5)
Pathologic stage
T1-2 15(14.7) 5(33.3) 10(66.7) 0.406
T3-4 87(85.3) 39(44.8) 48(55.2)
Node status
Negative 57(55.9) 20(35.1) 37(64.9) 0.065
Positive 45(44.1) 24(53.3) 21(46.7)
Nerve status
Negative 34(33.3) 16(47.1) 18(52.9) 0.572
Positive 68(66.7) 28(41.2) 40(58.8)
Vessel cancerous embolus
Negative 89(87.3) 42(47.2) 47(52.8) 0.031
Positive 13(12.7) 2(15.4) 11(84.6)
1Pearson’s chi-square test p-value
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VASH2 than the parental SW1990 cells transfected with
a scrambled shRNA (Additional file 3).
To determine the impact of these changes in
VASH2 expression on gemcitabine sensitivity, cellular
apoptosis was analyzed in these models after treat-
ment with 25 nM or 50 nM gemcitabine for 48 h.
VASH2 overexpression significantly reduced sensitiv-
ity to gemcitabine, as PANC-1-VASH2 cells exhibited
significantly decreased apoptosis compared to PANC-
1-EGFP cells after treatment with 25 nM gemcitabine
(12.69% ± 1.62% vs. 30.63% ± 2.65%, respectively; P <
0.05; Fig. 2) and 50 nM gemcitabine (17.47% ± 1.67%
vs. 39.71% ± 2.21%, respectively; P < 0.05; Fig. 2).
VASH2 knockdown significantly increased sensitivity
to gemcitabine, as SW1990-shVASH2 cells exhibited
significantly higher rates of apoptosis than SW1990-
scramble cells after treatment with 25 nM gemcita-
bine (25.52% ± 2.37% vs. 17.59% ± 1.63%, respectively;
P < 0.05; Fig. 2) and 50 nM gemcitabine (39.77% ±
2.22% vs. 30.93% ± 2.09%, respectively; P < 0.05; Fig. 2).
Without gemcitabine, the apoptosis rate of VASH2
overexpression/knockdown cells showed no significant
difference compared with control groups (Fig. 2, P >
0.05). These results indicate that VASH2 decreased
the gemcitabine sensitivity of pancreatic cancer cells
in vitro.
VASH2 decreased the sensitivity of pancreatic cancer cells
to gemcitabine in vivo
To further investigate the impact of VASH2 on pancre-
atic cancer sensitivity to gemcitabine in vivo we analyzed
the tumor control rate using a xenograft model of sub-
cutaneous tumor growth in nude mice. Images of whole
excised tumor masses are shown in Fig. 3a. Untreated
SW1990-shVASH2 tumors were smaller than SW1990-
scramble tumors (222.7 ± 44.6 mg vs. 367.6 ± 84.4 mg,
respectively; P < 0.05; Fig. 3b). When treated with gemci-
tabine, SW1990-shVASH2 tumors were smaller than
SW1990-scramble tumors (49.3 ± 28.9 mg vs. 195.0 ±
18.6 mg, respectively; P < 0.05, Fig. 3b). Untreated
PANC-1-VASH2 xenograft tumors had no significantly
different weight than PANC-1-EGFP tumors (137.2 ±
37.7 mg vs. 138.2 ± 64.0 mg, respectively; P > 0.05,
Fig. 3b). However, when treated with gemcitabine,
PANC-1-VASH2 tumors were significantly larger than
PANC-1-EGFP tumors (54.0 ± 27.2 mg vs. 12.2 ± 4.4 mg,
respectively; P < 0.05, Fig. 3b). To analyze the relation-
ship between VASH2 perturbation and gemcitabine
chemosensitivity, the tumor control rate was calculated
(the intervention factor was VASH2 overexpression or
knockdown). In SW1990 group, the tumor control rate
was significantly lower than SW1990-GZ group (Fig. 3c,
P < 0.05), and the tumor control rate of PANC-1 group
Fig. 2 VASH2 decreases the sensitivity of pancreatic cancer cells to gemcitabine in vitro. After treatment with 25 or 50 nM gemcitabine for 48 h,
the apoptosis rate of PANC-1-EGFP, PANC-1-VASH2, SW1990-scramble, and SW1990-shVASH2 was indicated by flow cytometric determination
of Annexin V and 7-AAD staining. Upper-right + lower-right quadrants indicate apoptotic cells. Apoptosis is quantified in the bar graphs for
PANC-1-EGFP and PANC-1-VASH2 (top) and SW1990-scramble and SW1990-shVASH2 (bottom). *P < 0.05
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was significantly higher than PANC-1-GZ group (Fig. 3c,
P < 0.05). These results suggest that VASH2 knockdown
in pancreatic cancer cells increases the growth inhibitory
effect of gemcitabine chemotherapy, and overexpression
of VASH2 reduces the growth inhibitory effect of gemci-
tabine chemotherapy.
TUNEL analysis was employed to determine the impact
of VASH2 modulation on apoptosis of pancreatic cancer
cells in vivo (representative images of TUNEL assay from
xenograft tumors shown in Fig. 3d). Following treatment
with gemcitabine, SW1990-shVASH2 with VASH2 knock-
down exhibited increased cellular apoptosis compared to
SW1990-scramble cells (48.8 ± 13.4 vs. 26.3 ± 6.7; P < 0.05;
Fig. 3e). After treatment with gemcitabine, PANC-1-
VASH2 cells overexpressing VASH2 demonstrated signifi-
cantly decreased apoptosis than PANC-1-EGFP cells (15.3
± 3.3 vs. 29.8 ± 10.3; P < 0.05; Fig. 3e). Without gemcita-
bine, there were no significant differences in apoptosis rate
between VASH2 overexpression/knockdown cells and
control cell lines (Fig. 3e). These data indicate that VASH2
can decrease the sensitivity of pancreatic cancer cells to
gemcitabine in vivo.
VASH2 regulates the expression of RRM2
Using the NimbleGen 12x135K microarrays, gene ex-
pression analysis were performed in PANC-1-EGFP/
PANC-1-VASH2 cells and differentially expressed genes
were identified through Fold Change filtering. Filtering
based on a threshold fold changes of ≥ 3 for upregulated
genes or ≤ 0.33 for downregulated genes identified 211
significantly upregulated genes and 192 significantly
downregulated genes (Additional file 4). RRM2, a typical
gemcitabine resistance associated gene was upregulated
by VASH2 (fold change = 3.27; Fig. 4a). RRM2 mRNA
and protein levels were detected in PANC-1-EGFP,
PANC-1-VASH2, SW1990-scramble, and SW1990-
shVASH2 cells. RRM2 expression was significantly
higher in PANC-1-VASH2 cells than in PANC-1-EGFP,
while RRM2 expression in SW1990-shVASH2 cells was
significantly lower than in SW1990-scramble cells
(Fig. 4b). Immunoblot analysis confirmed that RRM2
protein was expressed at higher levels in PANC-1-
VASH2 cells than PANC-1-EGFP cells, and at lower
levels in SW1990-shVASH2 cells than SW1990-scramble
cells (Fig. 4c). These data suggest that the gemcitabine
metabolism associated gene RRM2 is regulated by
VASH2.
Expression of VASH2 correlates positively with RRM2
expression in human pancreatic cancer
Human pancreatic cancer tissues from 102 patients
were subjected to immunohistochemical staining for
Fig. 3 Tumor control rate analysis using subcutaneous tumorigenesis in nude mice. Mice were divided into four groups: PANC-1 group (n = 6),
mice implanted with PANC-1-EGFP/PANC-1-VASH2 tumor pieces without gemcitabine chemotherapy; PANC-1-GZ group (n = 6), mice implanted
with PANC-1-EGFP/PANC-1-VASH2 tumor pieces with gemcitabine chemotherapy; SW1990 group (n = 7), mice implanted with SW1990-scramble/
SW1990-shVASH2 without gemcitabine chemotherapy; SW1990-GZ group (n = 7), mice implanted with SW1990-scramble/SW1990-shVASH2 with
gemcitabine chemotherapy. a resected xenograft tumors from all groups. b tumor mean weight analysis. c the tumor control rate of VASH2.
d and e representative images of and quantitation of TUNEL staining for apoptosis in the xenograft tumors, as determined by counting
1,000 cells in 6 randomly selected fields. The black arrows show the brown stained TUNEL-positive cells. *P < 0.05
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VASH2 and RRM2. Two representative examples are
presented in Fig. 4d. Typically, weak RRM2 immuno-
reactivity was observed in specimens that were weakly
positive for VASH2, whereas strong RRM2 immuno-
reactivity was detected in specimens that were
strongly positive for VASH2. In the 102 specimens,
VASH2 expression was significantly positively corre-
lated with RRM2 expression (Spearman’s rank correl-
ation coefficient = 0.41, P = 0.001).
JUN is induced by VASH2 and binds to the promoter of
RRM2, increases transactivation of RRM2
The promoter region of RRM2 was analyzed by SABios-
ciences (http://www.sabiosciences.com/chipqpcrsearch.php)
to determine the factor(s) reposnisble for transactivation of
of RRM2. Six potential transcription factors were identified:
Heat Shock Transcription Factor 2, Nuclear Factor Kappa
B Subunit 1, E2F Transcription Factor 1, Sp1 Transcription
Factor, CAMP Responsive Element Binding Protein, and
JUN. Of these, JUN was the only transcription factor
predicted to bind the RRM2 promoter that was among the
differentially expressed genes induced by VASH2 as deter-
mined from the NimbleGen 12x135K microarrays (fold
change = 3.94).
JUN protein and mRNA expression was detected
by western blotting and quantitative RT-PCR ana-
lyses, respectively, in PANC-1-EGFP, PANC-1-
VASH2, SW1990-scramble, and SW1990-shVASH2
cells. JUN mRNA and protein expression was signifi-
cantly upregulated by overexpression of VASH2 and
downregulated by knockdown of VASH2 expression
in the respective cell line models (Fig. 5a, b). Fur-
thermore, transfection with siRNA against JUN
mRNA resulted in a strong downregulation of JUN
and RRM2 protein in PANC-1-VASH2 cells (Fig. 5c;
siRNA knockdown of JUN mRNA demonstrated in
Additional file 5) siRNA. These results suggest that
the expression regulation of RRM2 by VASH2 was
JUN dependent.
Three JUN-binding sites were identified within RRM2
promoter using SABiosciences (http://www.sabiosciences.
com/chipqpcrsearch.php) and Jaspar software (http://jasp
ar.genereg.net/cgi-bin/jaspar_db.pl): (-2147/+1): BS1,
-1839/-1830; BS2, -1717/-1705; BS3, -643/-630 (Fig. 5d).
ChIP analysis demonstrated that JUN was recruited to the
BS3 locus but not BS1 or BS2 on the RRM2 promoter
(Fig. 5e). JUN protein was recruited to the BS3 locus in
the RRM2 promoter more efficiently in PANC-1-VASH2
cells than in PANC-1-EGFP cells, while less efficiently in
SW1990-scramble than SW1990-shVASH2 (Fig. 5e).
Using dual luciferase reporter assays, we investi-
gated whether JUN directly activates transcription of
RRM2. RRM2 promoter luciferase reporter plasmids
(PGL3-WT/PGL3-MUT) were co-transfected with a
Renilla luciferase expression plasmid (pRL-TK) with
or without a JUN expression plasmid in PANC-1,
PANC-1-VASH2, SW1990-scramble, and SW1990-
shVASH2 cells (Fig. 5f ). The relative promoter activity
was calculated as firefly luminescence/Renilla lumines-
cence. The mutant RRM2 promoter (PGL3-MUT) has
strongly reduced reporter activity compared to the
wild-type RRM2 promoter (PGL3-WT). Overexpres-
sion of JUN from a JUN expression plasmid increased
reporter activity from the wild-type RRM2 promoter
but not the mutant RRM2 promoter (Fig. 5g).
Reporter activity from the wild-type RRM2 promoter
Fig. 4 VASH2 regulates the expression of RRM2 and VASH2 expression correlates with RRM2 expression in human pancreatic cancer. a human
gene expression NimbleGen 12x135K microarrays within PANC-1-EGFP/PANC-1-VASH2 cells. Fold changes≥ 3 (upregulation; 211 genes) or ≤ 0.33
(downregulation, 192 genes) were selected as significantly altered genes for subsequent analysis. RRM2 (a typical gemcitabine resistance associated
gene) was upregulated by VASH2 (fold change = 3.27). b and c qPCR analysis and immunobloting test of RRM2 in PANC-1-VASH2, PANC-1-EGFP cells,
SW1990-shVASH2 and SW1990-scramble cells. d representative images of RRM2 and VASH2 staining in human pancreatic cancer tissues expressing
low (a) and high (b) levels of VASH2 are shown. (Spearman’s rank correlation coefficient, r = 0.41, P = 0.001). *P < 0.05
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but not from the mutant RRM2 promoter was signifi-
cantly increased in PANC-1-VASH2 cells compared
with PANC-1 cells, and significantly decreased in
SW1990-shVASH2 cells compared with SW1990-
scramble cells (Fig. 5g). The mutant RRM2 promoter
failed to elicit a response to either elevated endogenous
levels of JUN or to forced overexpression of JUN from the
JUN expression plasmid. These data indicate that VASH2
upregulates JUN and JUN activates RRM2 transcription
through direct binding to the RRM2 promoter, establish-
ing a JUN-dependent transactivation of RRM2 down-
stream of VASH2.
Discussion
VASH2 has been implicated in tumor progression
[5–12]. In this study, we investigated the expression
of VASH2 in human pancreatic cancer, and found
significantly higher levels of VASH2 in pancreatic
cancer tissues than in paired cancer-adjacent normal
tissue. VASH2 expression was associated with higher
tumor grade and more vessel cancerous embolus. Survival
analysis indicated that tumors that were negative/weak for
VASH2 staining were more sensitive to gemcitabine
chemotherapy than tumors exhibiting middle/strong
VASH2 staining, indicating that VASH2 may be related
Fig. 5 JUN is upregulated by VASH2, binds to the RRM2 promoter, and increases transactivation of RRM2. a and b qPCR analysis and immunobloting for
JUN in PANC-1-VASH2, PANC-1-EGFP, SW1990-shVASH2, and SW1990-scramble cells. c JUN and RRM2 immunobloting in PANC-1-EGFP and PANC-1-VASH2
transfected with siRNA against JUN. d diagram of three predicted JUN-binding sites within RRM2 promoter (-2147/+1) by SABiosciences and Jaspar
online software. e ChIP (JUN) analysis for three predicted JUN-binding sites of RRM2 promoter in PANC-1-EGFP, PANC-1-VASH2, SW1990-
scramble and SW1990-shVASH2 cells. f and g dual luciferase reporter assays for PGL3-WT/PGL3-MUT reporter activity co-transfected with
or without a JUN expression plasmid in PANC-1, PANC-1-VASH2, SW1990-scramble, and SW1990-shVASH2 cells. The relative promoter
activity was calculated as firefly luminescence/Renilla luminescence. *P < 0.05
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with gemcitabine sensitivity in pancreatic cancer. To fur-
ther investigate the involvement of VASH2 in gemcitabine
resistance, we created pancreatic cancer models of VASH2
overexpression and knockdown, and observed that
VASH2 inhibited gemcitabine-induced apoptosis in vitro
and in vivo.
Gemcitabine treatment is one of the main chemother-
apeutic approaches for advanced pancreatic cancer.
Gemcitabine has been shown to improve survival for
patients with pancreatic cancer, although the improve-
ment in survival time remains short, due to high rates of
resistance of pancreatic cancer to gemcitabine [17].
Sensitivity or resistance of pancreatic cancer cells to
gemcitabine can be regulated by the activity of genes
related to gemcitabine metabolism. Gemcitabine is taken
up into cells primarily by human concentrative nucleo-
side transporter 1 and 3 (hCNT1 and hCNT3) and by
human equilibrative nucleoside transporter (hENT1)
[18]. The expression of these nucleoside transporters is
correlated with chemosensitivity and patient survival
[19–23]. After being taken into the cells, gemcitabine is
activated by deoxycytidine (dCK) [24, 25]. Thus, hENT1,
hCNT1, hCNT3, and dCK positively contribute to gem-
citabine activity and to cancer cells' sensitivity to gemci-
tabine. On the other hand, ribonucleotide reductases
(RRM1 and RRM2) and multidrug resistance-associated
protein channels (MRP3, MRP4 and MRP 5) contribute
to gemcitabine resistance [26, 27].
Here we report that the gemcitabine metabolism
related gene, RRM2, is upregulated in pancreatic cancer
models of VASH2 overexpression. Furthermore, RRM2
expression was decreased in a pancreatic cell line model
with VASH2 knockdown. Immunohistochemical analysis
demonstrated that the expression of VASH2 was posi-
tively related to the RRM2 in human pancreatic cancer
tissues. Collectively, these results indicate that VASH2
induces gemcitabine resistance via upregulation of
RRM2 in human pancreatic cancer.
We discovered that the JUN transcription factor is
induced by VASH2 overexpression. Moreover, JUN is
the only transcription factor significantly differentially
expressed following perturbation of VASH2 expression
that is predicted to bind to the RRM2 promoter. JUN
was significantly upregulated in VASH2 overexpressing
cells and significantly downregulated in VASH2 knock-
down cells. siRNA againt JUN decreased RRM2 protein,
which was upregulated by VASH2. The regulation of
RRM2 expression by VASH2 was found to be JUN
dependent. Using SABiosciences and Jaspar online soft-
ware, three JUN binding sites were predicted within the
RRM2 promoter; ChIP analysis for JUN confirmed the
presence of a bonafide JUN-binding site in the RRM2
promoter. Using dual luciferase reporter assays, we con-
firmed that JUN directly activates the transcription of
RRM2. These data indicate that VASH2 can upregulate
JUN, leading to JUN-dependent transcriptional activa-
tion of RRM2 via direct binding to the RRM2 promoter.
It is intresting that SW1990-shVASH2 and SW1990-
scramble have a difference in their tumor weight, but
PANC-1-VASH2 and PANC-1-EGFP tumors do not have
(Fig. 3). This effect was also found in HepG2 cells and re-
ported by Xue Xiaofeng et al [5]. One possible reason was
that in the control of cell proliferation, PANC-1-EGFP
already had sufficient VASH2 expression, and the extra
VASH2 in PANC-1-VASH2 cells did not promote cell
proliferation. This effect was the same in vivo in SW1990-
shVASH2, SW1990-scramble, PANC-1-VASH2 and
PANC-1-EGFP cells (data not shown).
Conclusion
RRM2 has recently emerged as an important factor im-
plicated in the resistance to gemcitabine chemotherapy
[28–31]. Here, we found that VASH2 is expressed at
high levels in human pancreatic cancer cells and acts as
a gemcitabine-resistance factor, and the expression of
RRM2 could be upregulated by VASH2 in a JUN-
dependent manner. Therefore, VASH2 may represent a
novel target for anti-chemoresistance therapy in the
gemcitabine chemotherapy of pancreatic cancer; VASH2
may also be used as a marker to guide the gemcitabine
chemotherapy of pancreatic cancer. However, the precise
pathway by which VASH2 regulates JUN needs further
investigation.
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